Bioxcel Therapeutics, INC

BioXcel Therapeutics has entered into an Eleventh Amendment to its Credit Agreement, deferring a principal payment and reducing liquidity covenants.

BioXcel Therapeutics has entered into a Tenth Amendment to its Credit Agreement, deferring principal payments, reducing liquidity covenants, and initiating a strategic review process.

BioXcel Therapeutics reported Q1 2026 financial results, announced an FDA PDUFA date for IGALMI's at-home use, and is exploring strategic options to maximize shareholder value.

BioXcel Therapeutics issued warrants to purchase 1,353,729 shares of common stock to lenders in connection with the Ninth Amendment to its Credit Agreement.

The FDA has accepted BioXcel Therapeutics' supplemental New Drug Application for IGALMI for at-home treatment of agitation associated with bipolar disorders or schizophrenia.

BioXcel Therapeutics reported its full-year 2025 financial results and provided an update on its sNDA submission for IGALMI in the at-home setting, targeting potential approval by year-end 2026.

BioXcel Therapeutics reported increased product revenue but a wider net loss in Q1 2026, with ongoing concerns about its ability to continue as a going concern.

BioXcel Therapeutics, Inc. reported increased net losses and decreased product revenue for Q3 2025, while achieving positive safety and exploratory efficacy results in its SERENITY At-Home Phase 3 trial for agitation.

BioXcel Therapeutics reports substantial losses and declining product revenue, raising significant doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

BioXcel Therapeutics announces its Q1 2025 financial results, emphasizing the full enrollment of the SERENITY At-Home trial and providing updates on its clinical programs.

BioXcel Therapeutics announced its Q3 2024 results, highlighting a strategic shift towards BXCL501 clinical development and further workforce reductions to extend its cash runway.

BioXcel Therapeutics reports second quarter 2024 results, highlighting a strategic shift towards core clinical programs and a reduction in operating expenses.

BioXcel Therapeutics reported significant operating losses and declining product revenue for 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial data for IGALMI's at-home use and ongoing capital raises.

BioXcel Therapeutics faces financial headwinds but remains focused on clinical development of BXCL501 and exploring strategic options.

BioXcel Therapeutics' 10-K filing details the company's share structure, governance, and regulatory landscape, highlighting its focus on AI-driven drug development in neuroscience and immuno-oncology.

Chief Legal Officer Javier Rodriguez acquired 35 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.

BioXcel Therapeutics CFO Richard Steinhart acquired 35 shares of common stock through the vesting of restricted stock units.

Chief Scientific Officer Frank Yocca acquired 35 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.

CEO Vimal Mehta acquired 219 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.

Chief Scientific Officer Frank Yocca acquired 17,500 shares via RSU vesting and sold 6,845 shares to cover tax obligations.

Chief Legal Officer Javier Rodriguez sold 6,560 shares of BioXcel Therapeutics to cover tax obligations following an RSU vest.

BioXcel Therapeutics, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposed reverse stock split to maintain Nasdaq compliance.

BioXcel Therapeutics is asking stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

BioXcel Therapeutics has scheduled its 2024 Annual Meeting for June 10, 2024, and is seeking stockholder votes on several proposals, including the election of directors, ratification of the company's accounting firm, executive compensation, and amendments to the company's certificate of incorporation.

BioXcel Therapeutics is holding its annual stockholder meeting on June 10, 2024, to vote on key proposals including increasing authorized shares and officer exculpation.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7.05% of BioXcel Therapeutics, Inc. common stock as of March 31, 2026.

Qatar Investment Authority filed a Schedule 13G/A reporting beneficial ownership of 156,066 BioXcel Therapeutics shares (0.58%) held via Q Boost Holding LLC, including warrant shares.

Millennium Management and affiliated entities have reported an 8.4% beneficial ownership stake in BioXcel Therapeutics, Inc. as of December 31, 2025.

Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a passive beneficial ownership of 5.2% in BioXcel Therapeutics, Inc.

Oaktree Fund Advisors, Oaktree Capital Management, and affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 2.73% in BioXcel Therapeutics, Inc. through warrants.

Armistice Capital, LLC and its managing member Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. as of March 31, 2025.